Replimune's RP1 drug has garnered attention for its promising results in clinical trials. However, the current market dynamics suggest that it may not be the right time to invest.
Analysts have noted that while the drug shows potential, there are uncertainties that could affect its market performance. Investors are advised to consider these factors carefully.
In light of the mixed expert opinions, it may be prudent for investors to wait for further developments before making any purchasing decisions regarding Replimune's stock.